Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

Ashwani Garg, Kim Leitzel, Suhail Ali, Allan Lipton

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalCurrent Osteoporosis Reports
Issue number2
StatePublished - Apr 2015

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss'. Together they form a unique fingerprint.

Cite this